Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | BRAF | P15056 | 17/20 | 0.58 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.55 |
| ▸ | RAF1 | P04049 | 2/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.55 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.55 |
| ▸ | NEK2 | P51955 | 2/20 | 0.55 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.55 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.55 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.55 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.55 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 0.55 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.55 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.55 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.55 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.55 |
| ▸ | PLK4 | O00444 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3014832 | 0.88 | BRAF (0.56) | CYP2C9CYP2C19CYP3A4BRAFRIPK2 | |
| SCHEMBL855654 | 0.87 | CYP3A4 (0.62) | CYP2C9CYP2C19CYP3A4BRAFRIPK2 | |
| SCHEMBL413368 | 0.87 | CYP3A4 (0.62) | CYP2C9CYP2C19CYP3A4BRAFRIPK2 | |
| SCHEMBL12468027 | 0.86 | CYP3A4 (0.60) | CYP2C9CYP2C19CYP3A4BRAFRIPK2 | |
| SCHEMBL1492058 | 0.86 | CYP3A4 (0.60) | CYP2C9CYP2C19CYP3A4BRAFRIPK2 | |
| SCHEMBL1868892 | 0.85 | CYP3A4 (0.59) | CYP2C9CYP2C19CYP3A4BRAFRIPK2 | |
| SCHEMBL26393133 | 0.85 | BRAF (0.64) | CYP2C9CYP2C19CYP3A4BRAF | |
| SCHEMBL23098882 | 0.83 | CYP2C19 (0.56) | CYP2C9CYP2C19CYP3A4BRAFRIPK2 | |
| SCHEMBL16066858 | 0.83 | BRAF (0.57) | CYP2C9CYP2C19CYP3A4BRAFRIPK2 | |
| SCHEMBL8240987 | 0.80 | CYP3A4 (0.53) | CYP2C9CYP2C19CYP3A4BRAFRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858927-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| US-20210078995-A1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2021-03-18 | — | — | US | disclosed |
| CN-107722013-B | Deazapurine compounds, pharmaceutical compositions, preparation method and uses thereof | 中国科学院上海药物研究所 | 2021-01-12 | — | — | CN | disclosed |
| CN-109970733-B | Simple preparation method of vemurafenib and analogue thereof | 新发药业有限公司 | 2020-05-08 | — | — | CN | disclosed |
| US-10414764-B2 | Substantially pure vemurafenib and its salts | SHILPA MEDICARE LIMITED | 2019-09-17 | — | — | US | disclosed |
| WO-2019149738-A1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2019-08-08 | — | — | WO | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170320872-A1 | SUBSTANTIALLY PURE VEMURAFENIB AND ITS SALTS | SHILPA MEDICARE LIMITED (IN) | 2017-11-09 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2010104945-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2009111280-A1 | N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| EP-1893612-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | CYP2C9 4869/4885CYP2C19 4868/4885CYP3A4 4851/4885 |
| US-20210078995-A1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | MAPK4, MAP3K4, MAP4K1 | CYP2C9 2756/4885CYP2C19 4255/4885CYP3A4 971/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP2C9 4746/4885CYP2C19 4579/4885CYP3A4 4658/4885 |
| US-20170320872-A1 | SUBSTANTIALLY PURE VEMURAFENIB AND ITS SALTS | BRAF, RAF1, NRAS | CYP2C9 233/4885CYP2C19 393/4885CYP3A4 701/4885 |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CYP2C9 4746/4885CYP2C19 4579/4885CYP3A4 4658/4885 |
| US-11858927-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAP3K4, MAP4K1 | CYP2C9 2756/4885CYP2C19 4255/4885CYP3A4 971/4885 |
| US-10414764-B2 | Substantially pure vemurafenib and its salts | BRAF, RAF1, NRAS | CYP2C9 233/4885CYP2C19 393/4885CYP3A4 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.